Healthy Investment
Supported by
- – The value of sector annual production is Eur 308 mill.
- – Generic drugs development strategy
- – Cost efficiency & intellectual capacities
- – Market potentials & commitment to quality
Serbia Business produced several briefs on market status covering producers, distributors and local outsourced partners. Pharma sector in Serbia is one of the most perspective business areas.
Serbia Business also produced 2011/2010 pharma sector market report.
Supported by
Supported by
